Comparative efficacy of antimicrobial treatments in dairy cows at dry-off to prevent new intramammary infections during the dry period or clinical mastitis during early lactation: a systematic review and network meta-analysis

C. B. Winder1, J. M. Sargeant1,4, D. Hu2, C. Wang2, D. F. Kelton1, S. J. Leblanc1, T. F. Duffield1, J. Glanville3, H. Wood3, K. J. Churchill4, J. Dunn4, M. D. Bergevin4, K. Dawkins4, S. Meadows4, B. Deb4, M. Reist4, C. Moody4 and A. M. O’Connor2

1Department of Population Medicine, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada; 2Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames 50011-3619, USA; 3York Health Economic Consortium, University of York, York, YO10 5NG, UK and 4Centre for Public Health and Zoonoses, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada

Abstract

A systematic review and network meta-analysis were conducted to assess the relative efficacy of antimicrobial therapy given to dairy cows at dry-off. Eligible studies were controlled trials assessing the use of antimicrobials compared to no treatment or an alternative treatment, and assessed one or more of the following outcomes: incidence of intramammary infection (IMI) at calving, incidence of IMI during the first 30 days in milk (DIM), or incidence of clinical mastitis during the first 30 DIM. Databases and conference proceedings were searched for relevant articles. The potential for bias was assessed using the Cochrane Risk of Bias 2.0 algorithm. From 3480 initially identified records, 45 trials had data extracted for one or more outcomes. Network meta-analysis was conducted for IMI at calving. The use of cephalosporins, cloxacillin, or penicillin with aminoglycoside significantly reduced the risk of new IMI at calving compared to non-treated controls (cephalosporins, RR = 0.37, 95% CI 0.23–0.65; cloxacillin, RR = 0.55, 95% CI 0.38–0.79; penicillin with aminoglycoside, RR = 0.42, 95% CI 0.26–0.72). Synthesis revealed challenges with a comparability of outcomes, replication of interventions, definitions of outcomes, and quality of reporting. The use of reporting guidelines, replication among interventions, and standardization of outcome definitions would increase the utility of primary research in this area.

Introduction

Rationale

The majority of antimicrobial use in the dairy industry is for the treatment and prevention of intramammary infections (IMI); in the Netherlands, approximately 60% of all antimicrobial use in dairy is for this purpose, with two-thirds being dry cow therapy (Lam et al., 2012). In the United States, over 90% of dairy cows receive dry cow therapy after every lactation (USDA-APHIS, 2016), with the goal of treating or preventing IMI during the dry period. Prepartum IMI are strongly associated with the risk of development of clinical mastitis in the first 2 weeks post-calving, which represents the highest risk period for this disease (Green et al., 2002). In the United States, clinical mastitis represents the most common disease treated with antimicrobials in adult dairy cows, with approximately 16% of cows reported as having been treated in 2007, with cephalosporins the most commonly used drug class (United States Department of Agriculture, 2008). To reduce IMI during the dry period, blanket dry cow therapy (intramammary antimicrobial administration to all quarters of all cows after the last milking of the lactation) has been recommended for decades (Neave et al., 1969), and has been widely adopted in North America and the United Kingdom (Ruegg, 2017). However, choosing ineffective antimicrobials, or using antimicrobial when not warranted, unnecessarily contributes to use while having little impact on controlling disease, which has substantial bearing to both profitability and animal welfare (Leslie and Petersson-Wolfe, 2012). There is a need for evidence-based antimicrobial use protocols surrounding udder health (Ruegg, 2017). Systematic reviews of randomized controlled trials yield the highest...
level of evidence for the efficacy of treatment under field conditions (Sargeant et al., 2014a). If sufficient numbers of primary studies on a given comparison are available, a pairwise meta-analysis provides the relative efficacy of the two treatments. However, pairwise comparisons often rely on trials with non-treated controls as the comparison group, and direct comparisons of potentially comparable interventions may be limited (Roy and Keeffe, 2012). Previous systematic reviews have typically used pairwise meta-analysis to evaluate the efficacy of antimicrobial and non-antimicrobial interventions for dairy cattle at dry-off, including teat sealants (Halasa et al., 2009; Rabiee and Lean, 2013; Naqvi et al., 2018), antimicrobials (Robert et al., 2006; Halasa et al., 2009), and dry period length (van Knegsel et al., 2013). For intramammary treatments of cattle at dry-off, numerous interventions are available, including teat sealants used with or without one of several different dry-cow antimicrobial products. In these cases, pairwise meta-analyses only provide information about a single comparison, and do not provide a summary of evidence across multiple interventions (Cipriani et al., 2013). Network meta-analysis provides a method of assessing relative efficacy among many treatments by the use of both direct (studies which compare given treatments) and indirect (studies which share common comparators) evidence, and is a commonly used approach in human medicine (Caldwell et al., 2005; Cipriani et al., 2013).

Establishing the efficacy of cow-level antimicrobial therapy for the prevention of IMI and clinical mastitis will serve to improve decision makers’ ability to engage in effective stewardship of antimicrobials through the strategic use of these products with knowledge of implications for animal health and welfare.

This systematic review is conducted based on the guidance from the Cochrane Collaboration (Higgins and Green, 2011) and recommendations for conducting systematic reviews in animal agriculture and veterinary medicine (O’Connor et al., 2014a, 2014b; Sargeant and O’Connor, 2014a, 2014b; Sargeant et al., 2014a, 2014b). It is reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions (PRISMA-NMA) (Hutton et al., 2015).

Objective

The objective of this review was to determine the relative efficacy of antimicrobial administration at dry-off to prevent new IMI over the dry-period or clinical mastitis during early lactation.

Methods

Protocol

A review protocol, established in advance and reported in accordance with PRISMA-P guidelines (Moher et al., 2015), was published at the University of Guelph’s institutional repository (https://atrium.lib.uoguelph.ca/xmlui/handle/10214/10046) on 25 June 2018. The protocol is also available through Systematic Reviews for Animals and Food (SYREAF) (http://www.syreaf.org/contact/).

Eligibility criteria

Primary research studies, both refereed and non-refereed (grey literature), available in English were eligible for inclusion. Studies must have enrolled dairy cows after their first (or greater) lactation, without IMI at the cessation of milking (i.e. at dry-off) (for IMI outcomes), or without clinical mastitis at dry-off (for the clinical mastitis outcome). Studies must have included at least one treatment arm with an intramammary antimicrobial, with or without another concurrent dry cow treatment, compared to no treatment, placebo, or an alternative treatment (such as an internal or external teat sealant). To be eligible, studies must have included at least one outcome. Outcomes included (i) the incidence of IMI (using the author’s definition of IMI) during the pre-calving period following the intervention, (ii) the incidence of IMI during the first 30 days of the subsequent lactation and (iii) the incidence of clinical mastitis during the first 30 days of the subsequent lactation. Controlled trials with natural disease exposure were the only eligible study design, although challenge trials and analytical observational studies were documented during the full-text screening stage.

Information sources

Databases searched were: Agricola (via ProQuest, 1970 to current), CAB Abstracts and Global Health (via Web of Science, 1910 to current), Epub ahead of print, In-process & other non-indexed citations, Ovid MEDLINE®(R) Daily, and Ovid MEDLINE® (R) (via Ovid, 1946 to current), Conference Proceedings Citation Index – Science (via Web of Science, 1990 to current), and Science Citation Index (via Web of Science, 1900 to current). A reviewer hand-searched the table of contents of the following relevant conferences from 1997 to 2018: Proceedings of the American Association of Bovine Practitioners, World Association for Buiatrics, and the National Mastitis Council Proceedings. The Food and Drug Administration (FDA) website containing the Freedom of Information New Animal Drug Approvals (NADA) summaries was also searched.

Search

The search strategy initially was developed for the Science Citation Index (Web of Science) interface, and employed a multi-stranded approach to maximize the sensitivity (Table 1). The conceptual structure combined the concepts of ‘dairy cows’ AND ‘dry off’ AND ‘antimicrobials’; or ‘dry cow’ AND ‘antimicrobials’; or ‘dairy cows’ AND ‘prophylaxis’ AND ‘intra-mammary infections’. An additional precise search line to identify phrases such as ‘dry cow therapy’ and ‘dry cow management’ was also included in order to retrieve any records missed by the previous two combinations. Database searches were conducted on 28 June 2018. Search results were uploaded to EndNoteX7 (Clarivate Analytics, Philadelphia, PA, USA) and duplicate results documented and removed. Records were then uploaded to DistillerSR (Evidence Partners Inc., Ottawa, ON, USA) and additionally de-duplicated. If the same study and data were available as a conference abstract and as a full publication, the abstract was removed.

Validation of the search was done by identifying all articles included in the qualitative syntheses of reviews in the area of dry cow management as identified from the following papers: Robert et al., 2006; Halasa et al., 2009; Pereira et al., 2011; van Knegsel et al., 2013; Enger et al., 2016. All relevant articles identified in these reviews were found in the search.
is there a concurrent comparison group (i.e. controlled trial to assess the eligibility of the questions; agreement was at the level of the form. The following questions were used to assess the eligibility:

(1) Does the study involve antimicrobial-containing dry-cow treatments in dairy cattle at the individual level or an evaluation of group-level strategies for administering antimicrobial-containing dry-cow treatments (such as selective treatment versus blanket treatment)? YES (neutral), NO (exclude), UNCLEAR (neutral)

(2) Is there a concurrent comparison group (i.e. controlled trial with natural or deliberate disease exposure, or analytical observational study)? YES (neutral), NO (exclude), UNCLEAR (neutral)

(3) Is the full text available in English? YES (include for full-text screening), NO (exclude), UNCLEAR (include for full-text screening)

Citations were excluded if both reviewers responded ‘NO’ to any of the questions; agreement was at the level of the form. Disagreements were resolved by consensus with mediation by JMS or CBW if an agreement could not be reached. Secondary screening was conducted on the full text of remaining studies independently by two reviewers, using the first 10 citations as a pre-test by all reviewers. This level of screening used the initial three questions with only YES (neutral) or NO (exclude) options, and additionally:

(4) Does the study evaluate any of the following outcomes: incidence of clinical or subclinical mastitis at 30 days in milk

Table 1. Full electronic search strategy used to identify studies of antimicrobial treatments during the dry-off period in dairy cattle in Science Citation Index (Web of Science) conducted on 28 June 2018

| # | TS=| ("cow" OR "cows" OR "cattle" OR heifer* OR "dairy" OR "milking" OR bovine* OR "bovinae" OR buiaciana") | 466,726 |
| --- | --- | --- | --- |
| #2 | TS=( ayrshire* OR "brown swiss"* OR "basa" OR "basu" OR canadienne* OR dexter* OR "dutch belted"* OR "estonian red"* OR fleckvieh* OR friesian* OR girolando* OR guernesey* OR holstein* OR illawarra* OR "irish moiled"* OR jersey* OR "meuse rhine issel"* OR montbéliarde* OR normande* OR "norwegian red"* OR "red poll" OR "red pols" OR shorthorn* OR "short horn") | 54,025 |
| #3 | #2 OR #1 | 492,195 |
| #4 | TS=("drying off" OR "dry off" OR "dried off" OR "dried up" OR "drying up" OR "dried period"* OR "drying period" OR "dry udder"* OR "dry teat"* OR "pre-partum" OR "prepartum" OR ("[end]" OR finish* OR stop* OR ceas*) NEAR/3 lactat*) OR nonlactat* OR "non-lactat"* OR postlactat* OR "post-lactat"* OR postmilk* OR "post-milk"* OR "involvement" OR "steady state") | 237,049 |
| #5 | #4 AND #3 | 9,026 |
| #6 | TS=("dry cow" OR "dry cows") | 1,188 |
| #7 | #6 OR #5 | 9,708 |
| #8 | TS=("SDCT" OR "BDCT") | 143 |
| #9 | TS=("antimicrobial" OR "anti-microbial"* OR antibiotic* OR "anti-biotic"* OR antibacterial* OR "anti-bacterial"* OR anti-infect* OR bactericid* OR "bactericid"* OR microbicid* OR "microbicid"* OR antimycobacteri*) | 510,192 |
| #10 | TS=("albamacyn" OR "amoxicillin" OR "amoxycillin" OR "ampicillin" OR "benzathine" OR "cathomycin" OR "cefalexin" OR "cefastin" OR "cefaromycin" OR "cefelomycin" OR "ceftiofur" OR "cephalexin" OR "cephapirin" OR "cephalosporin" OR "cephaloridine" OR "cefloracin" OR "cefloridacin" OR CTC* OR "danofoxacin" OR "diclocaxilin" OR "dihydrostreptomycin" OR "enoxofloxacin" OR "erythromycin" OR "erythromycin"* OR "florfenicol" OR "framycetin" OR "gaminthomycin" OR "gentamicin" OR "gentamycine" OR "lincomycin" OR "lincomamide" OR "neomycin" OR "novobiocin" OR "oxytetracycline" OR "penethamate" OR "pencillin" OR "pirlimycin" OR "piperacillin" OR "spectomycin" OR "sulfadimethoxine" OR "sulfadimethoxin" OR "sulfamethoxazole" OR "sulfamethoxazole" OR "tetracycline" OR "tildipirosin" OR "trimethoprim" OR "tulathromycin" OR "tylosin") | 166,067 |
| #11 | #10 OR #9 OR #8 | 606,839 |
| #12 | #11 AND #7 | 719 |
| #13 | TS=("prophyxa" OR "chemoprophyla" OR "chemoprevent"* OR "chemo-prevent"* OR "metaphyla"* OR "meta-phyla"* OR "metapenumedicat"* OR "pre-medical") | 177,148 |
| #14 | TS=("mass" OR "blanket" OR "whole population"* OR "population wide" OR selectable* OR "targeted" OR prevent*) NEAR/5 (treat* OR therap* OR medicat* OR dosing* OR "administration") | 265,884 |
| #15 | #14 OR #13 | 430,368 |
| #16 | TS=("mastiti* OR ("intramammnar" OR "intra-mammar") NEAR/3 (infect* OR inflammm*)) | 16,611 |
| #17 | #16 AND #15 AND #7 | 182 |
| #18 | TS=("dry cow" OR "dry cows") NEAR/3 (therap* OR manag* OR intervention* OR treat* OR strateg*)) | 424 |
| #19 | #18 OR #17 OR #12 | 936 |

TS, topic field search (includes the title, abstract, author keywords, and keywords plus fields); *, unlimited right-hand truncation symbol; NEAR/N, retrieves records that contain terms (in any order) within a specified number (N) of words of each other.
(DIM), or incidence of IMI or subclinical mastitis at calving? YES (neutral) NO (exclude)

(5) What is the study design? Experimental – natural disease exposure (neutral), experimental – deliberate disease exposure (exclude), analytical observational study (exclude)

(6) Does the study evaluate a group-level strategy for administering dry-cow treatments (such as selective treatment versus blanket treatment)? YES (exclude from this review; included in a separate review), NO (include)

The term ‘subclinical mastitis’ was included as authors may have referred to this instead of IMI, but reflects the same disease. Agreement was at the question level, with conflicts resolved by consensus or with mediation by JMS or CBW if an agreement could not be reached.

**Data collection**

Data from citations meeting the full-text screening inclusion criteria were independently extracted by two reviewers using a standardized form, which was piloted on the first five citations by all reviewers to ensure consistency. Discrepancies in data extraction were resolved by consensus, with mediation by JMS and CBW if an agreement could not be reached. Hierarchical forms were used in DistillerSR for data extraction, with forms nested as: (Study Characteristics (Outcome (Arm, Contrast, Risk of bias))). A PDF version of the full data extraction tool is available as Supplemental File S1.

**Data items**

**Study characteristics**

Study-level data included study design, country of conduct, year and months of study conduct, setting (research or commercial herd), breed of cattle, number of herds enrolled, inclusion criteria at the cow and herd level, and parity of enrolled animals.

**Interventions and comparators**

Details on the interventions, including antimicrobial(s) used, route of administration, frequency of administration, dose, dry period length, level of treatment allocation, and level of analysis were recorded. Baseline characteristics and loss to follow-up were captured. Case definitions and times at which the outcomes were recorded, including which methods were used to identify IMI. Following data extraction, interventions were identified and labeled on a treatment map (Table 2). To provide strength to the network, interventions in the same antimicrobial family (World Organisation for Animal Health, 2007) were considered the same treatment protocol.

While results of all comparisons in the network were included in the analysis, only treatment arms with an intramammary antibiotic(s) and treatment groups were included. For included studies, information on other outcomes was extracted to describe their use in the literature, but data were not extracted for synthesis. These secondary outcomes were: total antimicrobial use during the first 30 days of lactation, total milk production over the next lactation, somatic cell count at the first milk recording test of the next lactation, average somatic cell count of the first three milk recording tests of the next lactation, and the risk of culling over the next lactation.

**Eligible outcomes**

Outcomes eligible for inclusion in the meta-analysis were:

- Incidence of clinical mastitis in the first 30 days of lactation,
- Incidence of IMI between treatment and calving, and
- Incidence of IMI in the first 30 days of lactation.

Prioritization of these outcomes for meta-analysis was determined during protocol development in consultation with content experts based on the frequency of use in the primary literature and being proxies to reflect the effects of infection during the dry period. Data reported for clinical mastitis were considered as incidence; cows were assumed to be free of clinical mastitis at dry-off unless otherwise reported in the study. For IMI incidence, cows were not assumed to be free of IMI at dry-off (according to the authors’ definition), and studies had to report results separately for ‘new’ infections to proceed to data extraction. What constituted a ‘new’ infection was recorded: no pathogen growth initially followed by any pathogen growth; a new pathogen isolated on the follow-up sample; or if this information was not reported.

For included studies, information on other outcomes was extracted to describe their use in the literature, but data were not extracted for synthesis. These secondary outcomes were: total antimicrobial use during the first 30 days of lactation, total milk production over the next lactation, somatic cell count at the first milk recording test of the next lactation, average somatic cell count of the first three milk recording tests of the next lactation, and the risk of culling over the next lactation.

For outcomes for which data were extracted, the prioritized outcome measure was an adjusted summary effect (adjusted odds ratio (OR) or relative risk or risk ratio (RR) for dichotomous outcomes, or adjusted least square mean differences for continuous outcome). Variables included in adjustment and the corresponding precision estimate were recorded. If an adjusted measure was not reported, unadjusted summary effect size (second priority) or treatment

---

**Table 2. Description of treatment groups as labeled in subsequent figures and tables**

| Figure label | Description |
|--------------|-------------|
| CEPH         | Intramammary cephalosporin |
| CLOX         | Intramammary cloxacinil |
| ERY          | Intramammary erythromycin |
| GENT         | Intramammary or parenteral gentamycin |
| QUIN         | Intramammary quinolone |
| PEN_AG       | Intramammary penicillin and aminoglycoside |
| PCS          | Intramammary penicillin, parenteral chloramphenicol, sulfa |
| TIL          | Intramammary or parenteral tilmicosin |
| TYL          | Intramuscular tylosin |
| NAC          | Untreated group (non-active control) |
| NOVO         | Intramammary or parenteral novobiocin |
| TS           | Internal teat sealant (bismuth subnitrate) |
| TS_CEPH     | Internal teat sealant (bismuth subnitrate) and intramammary cephalosporin |
| TS_CT        | Internal teat sealant (bismuth subnitrate), intramammary cephalosporin, and intramuscular tylosin |
| TS_CLOX      | Internal teat sealant (bismuth subnitrate) and intramammary cloxacinil |
| TS_PEN_AG    | Internal teat sealant (bismuth subnitrate) and intramammary penicillin and aminoglycoside |
| TS_TYL       | Internal teat sealant (bismuth subnitrate) and intramuscular tylosin |
A network meta-analysis was conducted for the outcome of IMI. Baseline risk mean were 1.0588 and 0.1864. The posterior mean and standard deviation of the baseline risk standard deviation process (Moura et al, 2019) were not linked to the network (i.e. did not have an intervention in common with one or more other published studies).

**Geometry of the network**

We visually evaluated the geometry of the network to determine if some pairwise comparisons dominated and to determine the network structure. We evaluated if there were intervention comparisons that were not linked to the network (i.e. did not have an intervention in common with one or more other published studies).

**Risk of bias in individual studies**

Risk of bias was assessed by outcome for all three outcomes extracted, using the Cochrane Risk of Bias 2.0 algorithm (Higgins et al., 2016), with signaling questions modified to be specific to the topic of the review. This tool assesses the potential for bias arising from five areas or domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in the measurement of the outcome, and bias in the selection of the reported results. In commodity groups such as swine or poultry, individual animal value is likely to be unknown or equal at the time of treatment allocation; for these livestock groups, the question on allocation sequence concealment may not be considered in the bias assessment for the domain related to the randomization process (Moura et al, 2019). In the case of dairy cattle, a decision was made to include the question on allocation concealment in the risk-of-bias assessment, as individual animal value is likely unequal and known at the time of treatment allocation in most (or all) studies. As well, an additional answer option was provided for the question on random allocation sequence, for studies using the word ‘random’ to describe the allocation sequence but not providing details on the method used to generate the random sequence.

Risk of bias was assessed independently in duplicate, with disagreement resolved by consensus and mediation by IMS or CBW if needed. The risk-of-bias tool is available as Supplementary File S2. For studies with each outcome, risk of bias for all studies is presented by outcome by domain of bias.

**Summary measures**

After extracting the outcomes, the analysis was conducted on the log OR for the analysis. For presentation purposes, the log OR was back-transformed to the RR using the baseline risk from the model data. The posterior mean and standard deviation of the baseline risk mean were –1.3610 and 1.0947. The posterior mean and standard deviation of the baseline risk standard deviation were 1.0588 and 0.1864.

**Network meta-analysis**

**Planned method of statistical analysis**

A network meta-analysis was conducted for the outcome of IMI at calving. The method has been previously described in detail elsewhere (Dias et al., 2010; O’Connor et al., 2013). Raw data or ORs were converted to a log OR, and RRs were converted to a log OR using the risk of disease in the control group. If probabilities were reported, the values were back converted to a log OR, using a process described by Hu et al. (2019).

**Selection of prior distributions in Bayesian analysis**

The prior distributions were originally based on the approach reported previously (Dias et al., 2011). For the model, \( \sigma \sim U(0,2) \) and \( \sigma \sim U(0,5) \) were assessed, and the analysis suggested \( \sigma \sim U(0,5) \) was preferred, so this prior was retained in the model.

**Implementation and output**

All posterior samples were generated using Markov Chain Monte Carlo (MCMC) simulation implemented using Just Another Gibbs Sampler (JAGS) software (version 3.4.0) (Plummer, 2015). All statistical analyses were performed using R software (version 3.2.1) (RCore, 2015) in a Linux system. The model was fit by calling JAGS from R through the RJAGS package (Plummer, 2015). Three chains were simulated and the convergence was assessed using Gelman–Rubin diagnostics. A total of 5000 ‘burn-in’ iterations were discarded, and based the inferences on a further 10,000 iterations. The model output included all possible pairwise comparisons using log ORs (for inconsistency assessment), RRs (used for comparative efficacy reporting), the rankings (for comparative efficacy reporting), and the probability of being the worst treatment option (for comparative efficacy reporting).

**Assessment of model fit**

The fit of the model was assessed based on the log OR, by examining the residual deviance between the predicted values from the mixed-treatment comparison model and the observed value for each study (Dias et al., 2010).

**Assessment of inconsistency**

Inconsistency was assessed by examining the consistency between direct and indirect evidence for all pairwise comparisons, using the method described by Dias et al. (2010). Means and standard deviations of log OR of treatment effects were calculated using direct (head-to-head) evidence only, indirect evidence only, and the combined evidence. We compared the estimates from the direct and indirect models and considered the standard deviation of each estimate, rather than relying on the P-values.

**Risk of bias in the overall network**

Risk of bias in the overall network of evidence was assessed using the Confidence In Network Meta-Analysis (CINEMa) platform (http://cinema.ispm.ch), which uses a frequentist approach through the ‘metafor’ package (Viechtbauer, 2010) to determine the basis for the contribution matrix for the risk of bias. CINEMa evaluates within-study bias, across-studies bias, indirectness, imprecision, heterogeneity, and incoherence. As opposed to presenting an overall assessment of bias and of indirectness, we reported the contribution of studies based on an approach to allocation to groups and blinding, as there is evidence in animal health that failure to include these design elements is associated with exaggerated treatment effects (Wellman and O’Connor, 2007; Burns and O’Connor, 2008; Sargeant et al., 2009a, 2009b). Risk of bias due to randomization was assessed as ‘low'
if the authors reported randomization and details of the method used to generate the sequence, ‘some concerns’ if random allocation was reported but no details on how the random sequence was generated were reported, and ‘high’ if no information on allocation was provided or if a non-random method was used. Risk of bias due to blinding was assessed as ‘low’ if both caregivers and outcomes assessors were blind to the treatment group, ‘unclear’ if caregivers or outcome assessors were blinded but not both, and ‘high’ if neither caregivers nor outcome assessors were blinded.

Indirectness (how closely the populations in the included studies resembled the target populations for the intervention) was not considered to be an issue due to the eligibility criteria for the review, and therefore the risk of bias was considered ‘low’ for all studies. Bias due to imprecision was assessed using 0.8 as a clinically important OR. Similarly, a 0.8 OR was used to assess heterogeneity. Incoherence (inconsistency) analysis was not reported from CINeMA as this was conducted using Bayesian analysis.

The process recommended to assess across-studies bias in an NMA is not well developed. Further, no pairwise comparisons in this review included more than 10 trials, which is the number typically believed to be necessary for an accurate across-studies bias assessment.
assessment (Sterne et al., 2000). Therefore, across-studies bias was not evaluated.

Results

Study selection

Results of the search and flow of studies through the screening process are presented in Fig. 1, including reasons for full-text exclusions. Full details on all searches are available as Supplemental File S3.

From an initial 3480 articles screened by title and abstract, 756 full texts were reviewed, with 697 not meeting full-text eligibility criteria, and 59 studies including 75 trials included after full-text screening. Of these 75 clinical trials, 35 had data that were not usable (e.g. data not presented, no variance measure provided for continuous outcomes, data presented in graphs or figures only, etc.). Therefore, data were extracted for one or more outcomes from 40 trials.

Study characteristics

Full details on study characteristics of the 40 trials with data extracted for one or more outcomes are included as Supplemental File S4. Studies were conducted in 12 countries, most frequently in the United States (n = 12), New Zealand (n = 4), and the United Kingdom (n = 3). The country of conduct was not reported in 30% of studies (n = 12). Study setting was most commonly a commercial dairy (28/40; 70%), with a small number of studies conducted at a research facility (7/40; 18%), or a combination of a research facility and commercial dairies (2/40; 5%). In three studies, the setting was not reported. The majority of studies did not report year of conduct (28/40; 70%), with eight studies (20%) conducted since 2000, and four studies (10%) conducted prior to 2000. Breed was reported in 21 (53%) studies, with Holstein/Friesian (n = 13; 33%) and cross-bred or multiple breeds (n = 8) being reported. Sixteen studies were conducted in a single herd (40%), and the number of herds ranged from 1 to 75. The number of herds was reported in all but one study.

Outcomes

Of the 40 included trials, IMI at calving was the most commonly reported outcome (n = 39), with three trials reporting the incidence of clinical mastitis in the first 30 DIM, and one reporting the incidence of IMI in the first 30 DIM. For additional outcomes in these included trials, two reported linear score (LS) or SCC at first test after calving, and one reported milk production over the subsequent lactation.

A new IMI was most commonly defined as the growth of a new pathogen on the follow-up sample (28/39; 72%), while eight trials (21%) defined new IMI as initially no pathogen growth on the dry-off sample, followed by growth of one or two pathogens on follow-up sampling. Three trials did not report how a new IMI was defined. Follow-up sampling was done at calving in 17 trials (44%), while the remaining trials measured from 1 to 15 DIM.

Risk of bias – IMI at calving

The results of the risk-of-bias assessment for the 36 trials included in the network meta-analysis are presented in Fig. 2, showing risk in the five evaluated domains for each outcome assessed in the network meta-analysis of IMI at calving. All trials were rated with an overall risk of bias as either ‘some concerns’ or ‘high’ (the trial’s highest risk of bias in any one domain).

For bias arising from the randomization process, all studies were assessed as ‘some concerns’. This was primarily driven by a lack of reporting, as only one trial reported if the allocation sequence was concealed when cows were assigned to intervention groups, and random allocation of treatment with information on the method used to generate the random sequence was reported in 15/36 trials (11%). An additional 15 trials reported random assignment of cows or quarter to treatment, but did not provide evidence of randomization, eight reported a non-random process (such as even- and odd-numbered ear tags), and nine did not provide sufficient information to assess this area.

Bias due to deviations from intended interventions in many studies was assessed as ‘some concerns’ (28/36; 78%), as blinding of caregivers and study personnel was uncommonly done. As
well, details regarding deviations from intended interventions were not often reported, although animals were commonly housed in mixed groups where differential care would be implausible. Bias due to missing outcome data was generally assessed as low risk (19/36; 53%), with 16 studies rated as some concerns, and one with a high risk of bias. ‘Some concerns’ resulted from a lack of reported information on loss to follow-up, and a ‘high’ risk of bias was due to a high level of missing data that was non-random or unequal between groups where results likely were not robust to the presence of missing data.

Bias due to measurement of the outcome was considered to be low in all trials, as although blinding of outcome assessors was rarely done (5/36; 14%), laboratory diagnoses were often used and considered relatively objective.

For bias arising from the selection of the reported results, information regarding a priori intentions of outcome measurements and analyses were not available for any studies; this domain generally requires the examination of a trial protocol or statistical analysis plan documented ahead of the trial if there are multiple ways an outcome could be measured or analyzed. As a result, all trials were assessed as ‘some concerns’ in this area.

**Results of individual studies**

Studies with data extracted but not included in the meta-analysis were a result of treatments being collapsed to a single arm per study (two trials), zero cells in event columns (one trial), or if the trial contained no treatment arms which linked to the network (zero trials). Of the 36 included trials, three reported adjusted data and 33 reported raw data. Thirty trials reported results at the quarter level, but only three trials controlled for clustering within the cow. Eighteen trials enrolled cows on multiple farms; two presented data adjusted for lack of independence within herd.

**Quantitative summary**

A network meta-analysis was conducted for trials examining the incidence of IMI at calving. No other analyses were conducted as very few studies were found that examined the incidence of IMI or clinical mastitis in the first 30 DIM for an informative network meta-analysis.

**Network meta-analysis – incidence of intramammary infection at calving**

The full network plot for IMI at calving is shown in Fig. 3; all treatments identified for this outcome were connected through one or more common trial arms. The network of evidence used in the meta-analysis is shown in Fig. 4, and represents 79 intervention arms from 36 trials, including 28 two-arm trials, six three-arm trials, one four-arm trial, and one five-arm trial. A full description of treatment acronyms used in Figs. 3 and 4 is given in Table 2.

**Assessment of consistency**

The consistency assessment for all direct and indirect comparisons is shown in Table 3. Means and standard deviations of log OR of treatment effects are shown using direct (head-to-head) evidence only, indirect evidence only, and the combined evidence. The inconsistency estimate and standard deviation are presented, and there was no evidence of significant inconsistency between direct and indirect estimates. The contribution of studies to estimates based on randomization status is presented in Fig. 5, and
the contribution of studies to estimates based on blinding in Fig. 6. Most pairwise comparisons (34/45) included a majority contribution from studies that did not report random allocation or reported a non-random method, while 9/45 had a majority contribution from studies describing random allocation with no supporting evidence. A small proportion of the contribution in some pairwise comparisons came from studies reporting random allocation to treatment with supporting evidence, but this was not the majority contribution for a single pairwise comparison. For contributions of studies to estimates based on blinding (Fig. 6), in most pairwise comparisons, there was only a very small, or no, contribution from studies reporting blinding of either caregiver or outcome assessor, and a smaller yet contribution from those reporting blinding of both. The majority contribution in 43/45 pairwise comparisons was from studies not reporting blinding of either caregivers or outcome assessors. Table 4 summarizes the majority contribution for each pairwise comparison for randomization and blinding, imprecision, and heterogeneity.

Rankings and distribution probability of IMI at calving

RRs from the network meta-analysis comparing all treatments are shown in Table 5. The RR is the risk of the event (IMI at calving) in the column header (numerator), divided by the risk of the event in the row header (denominator). For example, the estimated risk of IMI at calving was 2.68 times greater in non-active controls (NAC) compared to those given cephalosporin (CEPH) at dry-off. The corresponding confidence interval is located in the lower left-hand section of the table, with rows and columns reversed (95% CI 1.53–4.32). Mean rankings and 95% credibility intervals are presented as a forest plot (Fig. 7), and in Table 6 where rankings at the 2.5, 50, and 97.5% points of the distribution are shown. The distribution of the probability of treatment failure (probability of an IMI event at calving) is presented for each treatment in the network meta-analysis in Fig. 8a–c.

Risk of a new IMI at calving was higher for non-treated controls compared to cloxacillin (RR = 1.83, 95% CI 1.26–2.60), cephalosporins (RR = 2.68, 95% CI 1.53–4.32), and penicillin with aminoglycosides (RR = 2.36, 95% CI 1.38, 3.88). However, 95% credibility intervals had rankings that overlapped for non-treated controls, cloxacillin and penicillin with aminoglycosides. Between antimicrobial protocols, due to imprecision of estimation, differences in the RR of IMI at calving between antimicrobials were not observable.

Discussion

Multiple intervention options exist for cows at dry-off to prevent IMI and clinical mastitis. Relative efficacy is an important component of decision making, as rarely do producers or veterinarians only wish to know the efficacy of a product compared to a non-treated control, or to an incomplete set of comparators. While clinical perceptions of relative efficacy may be based on observations or anecdote, network meta-analysis provides an evidence-based instrument to afford decision makers with information regarding relative efficacy. In addition to relative efficacy, treatment decisions may be driven by multiple additional factors, including availability, cost (e.g. direct costs, discarded milk, residue risk, etc.), and importance to human health. With these in mind, relative efficacy can help inform decision making; for example, if two treatments are not different in efficacy, one with a lower cost, or lower importance to human health, can be selected. Similarly, the use of apparently ineffective products can be avoided to decrease unnecessary antimicrobial use.

Summary of evidence

Based on the evidence presented here, the use of a cephalosporin, cloxacillin, or penicillin with aminoglycoside appeared to be more effective than no treatment at preventing new IMI at calving, when given to cows without pre-existing IMI at dry off. However, the definition of a ‘new IMI’ varied, and may contribute to differences between studies.
The inconsistency estimate ($\omega_{XY}$) and standard deviation (SD) are shown. Posterior means (d) and standard deviation (SD) of the log-odds ratio of intervention effects calculated for direct (head-to-head) evidence only (dir), indirect evidence only (rest), and a combination of all evidence (MTC). The first treatment listed is the referent (denominator) and the second listed is the assessed as the comparator (numerator).

For the comparison of non-treated controls to cephalosporin, cloxacillin, or penicillin with aminoglycoside, imprecision was assessed as ‘no concerns’, which indicates that the 95% CI around the point estimate does not include values that would lead to different clinical decisions, based on a clinically significant OR of 0.8. However, some concerns were noted due to heterogeneity (cephalosporin, penicillin with aminoglycoside) and major concerns in the case of cloxacillin. This is a result of the 95% credibility interval not agreeing in relation to the predetermined clinically important effect, meaning the interval spans values which would lead to different clinical decisions. This indicates there are some between-study variations within these comparisons, which could be due (in part) to different study populations or definitions of the outcome. Examining the pairwise comparisons between antimicrobials, the majority had major concerns with regard to imprecision, meaning the 95% CI extends into the estimated ORs favoring either treatment (‘major concerns’). This may be driven by the small number of studies included for each unique combination.

### Table 3. Direct (dir) and indirect (rest) comparisons for the consistency assumption of pairwise comparisons within the network of studies examining the efficacy of antimicrobials given at dry-off to prevent new intramammary infections (IMI) at calving

| Comparison                  | d(dir) | SD(dir) | d(MTC) | SD(MTC) | d(rest) | SD(rest) | $\omega_{XY}$ | SD $\omega_{XY}$ | p     |
|-----------------------------|--------|---------|--------|---------|---------|----------|---------------|------------------|-------|
| TS versus TS_CEPH          | -0.22  | 1.38    | -0.22  | 0.62    | -0.23   | 0.69     | 0.01          | 1.54             | 1     |
| TS_CEPH versus TS_CLOX     | 0.15   | 2.91    | 0.12   | 0.48    | 0.12    | 0.49     | 0.03          | 2.95             | 0.99  |
| TS_CEPH versus TS_CT       | 0      | 2.91    | 0.16   | 0.79    | 0.17    | 0.82     | -0.18         | 3.03             | 0.95  |
| TS_CEPH versus TS_TYL      | -0.64  | 2.93    | 0.74   | 0.76    | 0.84    | 0.79     | -1.48         | 3.03             | 0.63  |
| TS_CEPH versus TYL         | 0.8    | 2.98    | 1      | 0.56    | 1.01    | 0.57     | -0.21         | 3.04             | 0.94  |
| TS_CT versus TS_TYL        | -0.6   | 2.87    | 0.57   | 0.89    | 0.7     | 0.93     | -1.3          | 3.02             | 0.67  |
| TS_CT versus TYL           | 0.76   | 2.98    | 0.84   | 0.79    | 0.85    | 0.82     | -0.09         | 3.1              | 0.98  |
| TS_TYL versus TYL          | 0.2    | 2.94    | 0.27   | 0.76    | 0.27    | 0.79     | -0.07         | 3.04             | 0.98  |
| NAC versus TIL             | -0.35  | 1.26    | -0.64  | 0.33    | -0.66   | 0.34     | 0.31          | 1.3              | 0.81  |
| NAC versus TS_CLOX         | -1.82  | 1.64    | -1.4   | 0.34    | -1.38   | 0.35     | -0.44         | 1.68             | 0.79  |
| NAC versus TS_PEN_AG       | -1.63  | 2.91    | -1.57  | 0.45    | -1.57   | 0.46     | -0.05         | 2.94             | 0.99  |
| NAC versus CLOX            | -0.75  | 0.24    | -0.73  | 0.18    | -0.7    | 0.26     | -0.05         | 0.35             | 0.89  |
| NAC versus CEPH            | -1.34  | 0.74    | -1.14  | 0.24    | -1.12   | 0.25     | -0.23         | 0.79             | 0.77  |
| NAC versus NOVO            | -0.73  | 2.02    | -0.21  | 0.51    | -0.17   | 0.52     | -0.56         | 2.08             | 0.79  |
| NAC versus PCS             | -0.65  | 2.89    | -1.06  | 0.42    | -1.07   | 0.42     | 0.42          | 2.93             | 0.89  |
| NAC versus PEN_AG          | -0.89  | 1.89    | -1     | 0.26    | -1      | 0.26     | 0.11          | 1.91             | 0.96  |
| CLOX versus TIL            | -0.51  | 2.9     | 0.09   | 0.28    | 0.09    | 0.28     | -0.6          | 2.91             | 0.84  |
| CLOX versus TS_CLOX        | 0.14   | 2.87    | -0.67  | 0.29    | -0.68   | 0.3      | 0.83          | 2.88             | 0.77  |
| CLOX versus ERY            | 1.18   | 2.96    | 1.18   | 0.82    | 1.18    | 0.85     | 0.01          | 3.08             | 1     |
| CLOX versus GENT           | -0.41  | 2.88    | -0.31  | 0.57    | -0.31   | 0.58     | -0.1         | 2.94             | 0.97  |
| CLOX versus CEPH           | 0.45   | 2.93    | -0.41  | 0.21    | -0.42   | 0.22     | 0.87          | 2.94             | 0.77  |
| CLOX versus PCS            | -0.67  | 2.89    | -0.33  | 0.36    | -0.33   | 0.37     | -0.34         | 2.92             | 0.91  |
| CLOX versus PEN_AG         | -0.36  | 0.84    | -0.27  | 0.23    | -0.26   | 0.24     | -0.09         | 0.88             | 0.92  |
| CLOX versus QUIN           | -0.18  | 2.92    | -0.03  | 0.44    | -0.03   | 0.44     | -0.15         | 2.95             | 0.96  |
| GENT versus QUIN           | -0.19  | 2.94    | 0.28   | 0.58    | 0.3     | 0.59     | -0.49         | 3                | 0.87  |
| CEPH versus TS_CLOX       | 0.3    | 1.22    | -0.26  | 0.3     | -0.3    | 0.31     | 0.59          | 1.26             | 0.64  |
| CEPH versus PEN_AG        | 0.05   | 1.64    | 0.14   | 0.25    | 0.15    | 0.25     | -0.1          | 1.66             | 0.95  |
| PCS versus PEN_AG         | -0.34  | 2.87    | 0.06   | 0.37    | 0.07    | 0.37     | -0.41         | 2.89             | 0.89  |
| PEN_AG versus TS_PEN_AG   | -0.53  | 2.9     | -0.58  | 0.39    | -0.58   | 0.4      | 0.05          | 2.92             | 0.99  |
| PEN_AG versus TYL         | 0.65   | 2.94    | 0.48   | 0.5     | 0.47    | 0.5      | 0.18          | 2.98             | 0.95  |
| PEN_AG versus QUIN        | 0.5    | 2.93    | 0.24   | 0.43    | 0.23    | 0.44     | 0.27          | 2.96             | 0.93  |
| QUIN versus TIL           | -0.22  | 2.92    | 0.24   | 0.54    | 0.26    | 0.55     | -0.47         | 2.97             | 0.87  |
Fig. 5. The contribution of studies to the point estimate based on the description of allocation approach for studies contributing to the network meta-analysis examining the relative efficacy of antimicrobial treatments given at dry-off to prevent intramammary infections (IMI) at calving ($n = 36$). Green indicates studies that randomly allocated to treatment and provided evidence of random sequence generation, yellow indicates studies that reported random allocation but did not provide supporting evidence, and red indicates studies that did not report allocation approach or reported a non-random method. White vertical lines indicate the percentage contribution of separate studies.
Fig. 6. The contribution of studies to the point estimate based on the description of blinding for studies contributing to the network meta-analysis examining the relative efficacy of antimicrobial treatments given at dry-off to prevent intramammary infections (IMI) at calving (n = 36). Green indicates studies that reported both caregivers and outcome assessors were blinded to treatments, yellow indicates studies that reported caregivers or outcome assessors were blinded to treatment (but not both), and red indicates studies where blinding was not used, or not reported, for both caregivers and outcome assessors. White vertical lines indicate the percentage contribution of separate studies.
Table 4. Summary of the overall quality of evidence of the network of studies examining the efficacy of antimicrobial treatments given at dry-off to prevent new intramammary infections (IMI) at calving, using the Confidence In Network Meta-Analysis (CINeMA) platform (http://cinema.ispm.ch), with a modified approach, to determine the risk of bias due to approach to randomization, blinding, imprecision, and heterogeneity.

| Comparison       | Number of studies | Randomization | Blinding | Imprecision | Heterogeneity |
|------------------|-------------------|---------------|----------|-------------|---------------|
| CEPH:CLOX        | 1                 | Some concerns | Major concerns | Some concerns | Some concerns |
| CEPH:NAC         | 4                 | Some concerns | Major concerns | No concerns  | Some concerns |
| CEPH:PEN_AG      | 2                 | Major concerns | Major concerns | Major concerns | No concerns  |
| CLOX:ERY         | 1                 | Major concerns | Major concerns | Major concerns | No concerns  |
| CLOX:GENT        | 1                 | Major concerns | Major concerns | Major concerns | No concerns  |
| CLOX:NAC         | 8                 | Major concerns | Major concerns | No concerns  | Major concerns |
| CLOX:PEN_AG      | 3                 | Some concerns | Major concerns | Some concerns | Some concerns |
| CLOX:QUIN        | 1                 | Major concerns | Major concerns | No concerns  | No concerns  |
| CLOX:TIL         | 1                 | Some concerns | Major concerns | No concerns  | No concerns  |
| GENT:QUIN        | 1                 | Major concerns | Major concerns | No concerns  | No concerns  |
| NAC:NOVO         | 2                 | Major concerns | Major concerns | No concerns  | No concerns  |
| NAC:PEN_AG       | 2                 | Some concerns | Major concerns | No concerns  | Some concerns |
| NAC:TIL          | 2                 | Some concerns | Major concerns | No concerns  | Some concerns |
| PEN_AG:QUIN      | 1                 | Major concerns | Major concerns | No concerns  | No concerns  |
| PEN_AG:TYL       | 1                 | Major concerns | Major concerns | No concerns  | No concerns  |
| QUIN:TYL         | 1                 | Major concerns | Major concerns | No concerns  | No concerns  |
| CEPH:ERY         | 0                 | Major concerns | Major concerns | Some concerns | Some concerns |
| CEPH:GENT        | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| CEPH:NOVO        | 0                 | Major concerns | Major concerns | Some concerns | Some concerns |
| CEPH:QUIN        | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| CEPH:TIL         | 0                 | Some concerns | Major concerns | Some concerns | Some concerns |
| CEPH:TYL         | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| CLOX:NOVO        | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| CLOX:TIL         | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| ERY:GENT         | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| ERY:NAC          | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| ERY:NOVO         | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| ERY:PEN_AG       | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| ERY:QUIN         | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| ERY:TIL          | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| GENT:NAC         | 0                 | Major concerns | Major concerns | Some concerns | Some concerns |
| GENT:NOVO        | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| GENT:PEN_AG      | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| GENT:TIL         | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| GENT:TYL         | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| NAC:QUIN         | 0                 | Major concerns | Major concerns | Some concerns | Some concerns |
| NAC:TIL          | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| NOVO:PEN_AG      | 0                 | Major concerns | Major concerns | Some concerns | Some concerns |
| NOVO:QUIN        | 0                 | Major concerns | Major concerns | No concerns  | No concerns  |
| NOVO:TIL         | 0                 | Some concerns | Major concerns | No concerns  | No concerns  |

(Continued)
heterogeneity (all would be ranked as ‘no concerns’ simply based on the wide 95% CI).

All treatments found in the studies meeting criteria for data extraction were connected by one or more intervention arms, which allowed for estimates of relative efficacy for all interventions extracted. When treatment arms are not common to multiple trials, the utility of the original research is impaired.

Blinding of caregivers and outcome assessors was uncommonly reported for studies evaluating the incidence of IMI at calving (Fig. 6); however, as this outcome is objective, this resulted in a low overall risk of bias due to the assessment of the outcome component (Fig. 2). However, bias arising from missing outcome data was observed in some trials, which in some cases was due to a lack of reporting of the number of study units analyzed. The Reporting guidElines for randomized control trials in livEstoCk and food safTey (REFLECT) statement recommends that authors report the flow of study units through each stage of the study, including the number allocated, receiving the intervention, completing the protocol, and analyzed for each outcome, with the use of a diagram recommended (O’Connor et al., 2010; Sargeant et al., 2010).

Randomization was done in some (4/36) trials, but non-random allocation, such as assignment by even or odd ear tag number, was conducted in several, and many did not report the method of allocation. There is evidence that reporting of randomization has improved since the publication of reporting guidelines such as the REFLECT statement (Totton et al., 2018). However, reporting specific to dairy science revealed that although 104 of a sample of 137 trials published in 2017 reported random allocation to study group, only seven reported the method of randomization (Winder et al., 2019). Assumptions for many statistical methods rely on interchangeable groups, and failure to randomize has been shown to be associated with exaggerated treatment effects (Burns and O’Connor, 2008; Sargeant et al., 2009a; Brace et al., 2010). Even in trials of genetically identical mice, failure to randomize has shown similar associations (Egan et al., 2016).

**Limitations of the body of literature**

Despite a large number of trials in this area, there was a limited number of studies eligible to be combined in the meta-analysis (Fig. 1). Lack of comparable outcomes and inadequate presentation of required data were the most common reasons for the exclusion of trials from the network. However, these limitations of a sparse body of comparable work pertain to any research synthesis approach.

Case definition varied within the single outcome of IMI at calving. The exact role of existing minor pathogen IMI on the risk of new major pathogen IMI is unclear, as a protective effect has been reported in challenge trials, but not observational studies, and there is a large amount of heterogeneity in these data (Reyher et al., 2012). If the existing infection does influence the risk of a new infection, then it is important that primary research consider this and ensure adequate reporting of the case definition. Risk period was also variable among studies, which, assuming this has influence on outcomes, limits the ability to further utilize this body of research. Standardized outcomes with biological meaning for a given intervention would strengthen the value of primary research. In human health, efforts to standardize outcome measures exist in multiple research areas (Williamson et al., 2012; Macefield et al., 2014).

---

**Table 4.** Continued.

| Comparison   | Number of studies | Randomization | Blinding | Imprecision | Heterogeneity |
|--------------|-------------------|---------------|----------|-------------|---------------|
| NOVO:TYL     | 0                 | Major concerns| Major concerns| Major concerns| No concerns   |
| PEN_AG:TIL   | 0                 | Some concerns | Major concerns| Major concerns| No concerns   |
| QUIN:TIL     | 0                 | Major concerns| Major concerns| Major concerns| No concerns   |
| TIL:TYL      | 0                 | Major concerns| Major concerns| Major concerns| No concerns   |

Imprecision and heterogeneity were determined using a clinically important odds ratio of 0.8.

**Table 5.** Risk ratio comparison of all interventions assessed in the network meta-analysis for the outcome of IMI at calving

| Comparison       | Number of studies | Randomization | Blinding | Imprecision | Heterogeneity |
|------------------|-------------------|---------------|----------|-------------|---------------|
| NAC              | 1.83              | 0.96          | 2.87     | 2.68        | 1.31          | 2.36          | 2.08          | 1.75          | 1.74          |
| (1.26_2.06)      | CLOX              | 0.53          | 1.56     | 1.48        | 0.73          | 1.3           | 1.14          | 0.97          | 0.96          |
| (0.23_3.04)      | ERY               | 4.52          | 4.27     | 2.07        | 3.74          | 3.27          | 2.77          | 2.74          |
| (0.86_8.13)      | GENT              | 1.27          | 0.63     | 1.11        | 0.9           | 0.84          | 0.8           |
| (1.53_4.32)      | CEPH              | 0.52          | 0.91     | 0.81        | 0.69          | 0.68          |
| (0.58_2.91)      | NOVO              | 2.13          | 1.87     | 1.58        | 1.57          |
| (1.38_3.88)      | PEN_AG            | 0.78          | 0.76     |
| (0.86_4.81)      | QUIN              | 1.01          | 0.93     |
| (1.308)          | TIL               | 1.07          |
| (0.65_4.31)      | TYL               |

The upper right-hand section of the table represents the risk ratio between the numerator (upper left treatment) and denominator (lower right treatment). The lower left section of the table represents the 95% CI. (0.34_7.15) (0.12_1.91) (0.19_1.2) NOVO 2.13 1.87 1.58 1.57 (0.82_2.03) (0.74_1.16) (0.29_2.83) (0.52_1.5) (0.75_4.77) PEN_AG 0.9 0.78 0.76 (0.47_2.48) (0.54_11.19) (0.25_2.26) (0.3_1.64) (0.49_5.09) (0.35_1.95) QUIN 1.01 0.93 (0.52_1.68) (0.53_8.65) (0.19_2.24) (0.32_1.29) (0.5_3.66) (0.36_1.45) (0.32_2.35) TIL 1.07 (0.34_2.31) (0.42_9.79) (0.16_2.36) (0.22_1.66) (0.37_4.47) (0.26_1.78) (0.31_2.22) (0.32_2.81) TYL
Confidence intervals surrounding the more commonly replicated interventions were also quite wide. This highlights the need for replication, in order to derive more precise estimates of efficacy and appropriately rank treatments, for interventions of interest to end users.

Limitations of the review

A large number of studies were excluded at full-text screening as they were not available in English, and as a result, our conclusions may not reflect the entirety of literature assessing the efficacy of dry-cow antimicrobial therapy on the prevention of IMI and CM. Although it is unlikely that language would be associated with different estimates of effect, additional studies would have increased the precision of estimation.

Additionally, the outcome assessed in the network (IMI at calving) likely reflects a variety of pathogens, which may differ between study populations. The efficacy of each antimicrobial for prevention may differ by an agent based on the differences in pharmacology, and this may have accounted for some of the heterogeneity seen across studies. Treatments were grouped based on OIE antimicrobial category, and therefore there may be differential effects of specific antimicrobials (e.g. product, dose) within a collapsed category. However, assigning each product and dose to a unique treatment would have resulted in an increasingly sparse network, and we attempted to be transparent with how these data were grouped for analysis.

Conclusions

From the network of evidence produced by this analysis, it was apparent that the use of cephalosporins, cloxacillin, or penicillin with aminoglycoside given to cows without existing IMI at dry-off provided a significantly protective effect for the development of new IMI at calving, compared to non-treated controls. There were no apparent differences among these antimicrobials. However, the precision of the estimates of the comparisons among antimicrobials was of major concern due to wide confidence intervals on the estimated rankings, meaning it is possible the true effects of some of these treatments are not equivalent. Synthesis of the primary research revealed challenges with comparable outcomes, replication and connection of interventions, and quality of reporting of study conduct in order to assess the potential risk of bias in the reported results. Consideration of the use of reporting guidelines by journals and authors, and

![Forest plot of mean rank and 95% credibility interval for the network meta-analysis examining the relative efficacy of antimicrobial treatments given at dry-off to prevent intramammary infections (IMI) at calving. Full treatment arm descriptions are presented in Table 2.](https://doi.org/10.1017/S1466252319000239)
standardized outcomes would increase the value of primary research in this area.

**Supplementary material.** The supplementary material for this article can be found at [https://doi.org/10.1017/S1466252319000239](https://doi.org/10.1017/S1466252319000239).

**Author contributions.** CBW assisted with the development of the review protocol, co-coordinated the research team, assisted with data screening, extraction, and risk of bias assessment, interpreted the results, and wrote the manuscript drafts. JMS developed the review protocol, co-coordinated the research team, interpreted the results, commented on manuscript drafts, and approved the final manuscript. DH conducted the data analysis, provided guidance for the interpretation of results, commented on manuscript drafts, and approved the final manuscript. CW assisted with the development of the review protocol, provided guidance on the conduct of the analysis and interpretation of results, and approved the final manuscript. AMOC, DFK, SJL, and TFD co-developed the review protocol, provided guidance on the interpretation of results, commented on manuscript drafts, and approved the final manuscript.

**Financial support.** Support for this project was provided by The Pew Charitable Trusts.

**Conflict of interest.** None of the authors has conflicts to declare.

**References**

Brace S, Taylor D and O’Connor AM (2010) The quality of reporting and publication status of vaccines trials presented at veterinary conferences from 1988 to 2003. *Vaccine* 28, 5306–5314.

Burns MJ and O’Connor AM (2008) Assessment of methodological quality and sources of variation in the magnitude of vaccine efficacy: a systematic review of studies from 1960 to 2005 reporting immunization with *Moraxella bovis* vaccines in young cattle. *Vaccine* 26, 144–152.

Caldwell DM, Ades AE and Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ* 331, 897–900.

Cipriani A, Higgins JP, Geddes JR and Salanti G (2013) Conceptual and technical challenges in network meta-analysis. *Annals of Internal Medicine* 159, 130–137.

Dias S, Welton NJ, Caldwell DM and Ades AE (2010) Checking consistency in mixed treatment comparison meta-analysis. *Statistics in Medicine* 29, 932–944.

Dias S, Welton NJ, Sutton AJ and Ades AE (2011) *NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials*. Sheffield: Unit NDS.

Egan KJ, Vesterinen HM, Beglopoulos V, Sena ES and Macleod MR (2016) From a mouse: systematic analysis reveals limitations of experiments testing...
interventions in Alzheimer’s disease mouse models. Evidence-based Preclinical Medicine 3, e00015.

Enger BD, White RR, Nickerson SC and Fox LK (2016) Identification of factors influencing teat dip efficacy trial results by meta-analysis. Journal of Dairy Science 99, 9900–9911.

Green MJ, Green LE, Medley GF, Schukken YH and Bradley AJ (2002) Influence of dry period bacterial intramammary infection on clinical mastitis in dairy cows. Journal of Dairy Science 85, 2589–2599.

Halasa T, Osteras O, Hogeven H, van Werven T and Nielen M (2009) Meta-analysis of dry cow management for dairy cattle. Part 1. Protection against new intramammary infections. Journal of Dairy Science 92, 3134–3149.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ and Welch S (eds) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.train-ing.cochrane.org/handbook.

Higgins JPT, Sterne JA, Savovic J, Page MJ, Hróbjartsson A and Boutron I (2011) Systematic Reviews of interventions in Alzheimer disease mouse models. Cochrane Database of Systematic Reviews 10(supp. 1), 29–31.

Hu D, Wang C and O Neave FK, Dodd FH, Kingwill RG and Westgarth DR (2011) The REFLECT statement: methods and explanation and elaboration. Preventive Veterinary Medicine 91, 107–115.

Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, Leslie KE and Petersson-Wolfe CS (2012) Assessment and management of pain in dairy cows with clinical mastitis. Veterinary Clinics of North America: Food Animal Practice 28, 289–305.

Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST, Leslie KE and Petersson-Wolfe CS (2012) Assessment and management of pain in dairy cows with clinical mastitis. Veterinary Clinics of North America: Food Animal Practice 28, 289–305.

Mayer PS, Ramirez A, Sischo W, Smith DR, Snedeker P, Sofos J, CE, Dohoo IR, Evans RB, Gray JT, Greiner M, Keefe G, Lefebvre SL, Sullivan TL, Linhares DCL and Sprangers MAG and Blazeby JM (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 4, 1.

Mora CAA, Totton SC, Sargeant JM, O’Sullivan TL, Linhares DCL and O’Connor AM (2019) Evidence of improved reporting of swine intervention trials in the post-REFLECT statement publication period. Journal of Swine Health and Production 27, 265–277.

Naqvi S, De Buck J, Dufour S and Barkema HW (2018) Udder health in Canadian dairy heifers during early lactation. Journal of Dairy Science 101, 3233–3247.

Neave FK, Dodd FH, Kingwill RG and Westgarth DR (1969) Control of mastitis in the dairy herd by hygiene and management. Journal of Dairy Science 52, 696–707.

O’Connor AM, Sargeant JM, Gardner IA, Dickson JS, Torrence ME, Dewey CE, Dohoo IR, Evans RB, Gray JT, Greiner M, Keefe G, Lefebvre SL, Morley PS, Ramirez A, Sischo W, Smith DR, Snedeker P, Sofos J, Ward MP and Wills R (2010) The REFLECT statement: methods and processes of creating reporting guidelines for randomized controlled trials for livestock and food safety. Journal of Veterinary Internal Medicine 24, 57–64.

O’Connor AM, Anderson KM, Goodell CK and Sargeant JM (2014a) Conducting systematic reviews of intervention questions I: writing the review protocol, formulating the question and searching the literature. Zoonoses and Public Health 61(suppl. 1), 28–38.

O’Connor AM, Coetzee JF, da Silva N and Wang C (2013) A mixed treatment comparison meta-analysis of antibiotic treatments for bovine respiratory disease. Preventative Veterinary Medicine 110, 77–87.

O’Connor AM, Sargeant JM and Wang C (2014b) Conducting systematic reviews of intervention questions III: synthesizing data from intervention studies using meta-analysis. Zoonoses and Public Health 61(suppl. 1), 52–63.

Pereira UP, Oliveira DG, Mesquita LR, Costa GM and Pereira LJ (2011) Efficacy of staphylococcus aureus vaccines for bovine mastitis: a systematic review. Veterinary Microbiology 148, 117–124.

Plummer M (2015) RJAGS: Bayesian graphical models using MCMC. R. Package version 3.5. Available at http://CRAN.R-project.org/package=rjags.

R Core Team (2015) R: A Language and Environment for Statistical Computing. R Foundation For Statistical Computing, Vienna: Austria. Available at https://www.R-project.org.

Rabbee AR and Lean JI (2013) The effect of internal teat sealant products (teat seal and orbeseal) on intramammary infection, clinical mastitis, and somatic cell counts in lactating dairy cows: a meta-analysis. Journal of Dairy Science 96, 6915–6931.

Reyher KF, Haine D, Dohoo IR and Revie CW (2012) Examining the effect of intramammary infections with minor mastitis pathogens on the acquisition of new intramammary infections with major mastitis pathogens—a systematic review and meta-analysis. Journal of Dairy Science 95, 6483–6502.

Robert A, Seegers H and Bareille N (2006) Incidence of intramammary infections during the dry period without or with antibiotic treatment in dairy cows – a quantitative analysis of published data. Veterinary Research 37, 25–48.

Roy JP and Keefe G (2012) Systematic review: what is the best antibiotic treatment for staphylococcus aureus intramammary infection of lactating cows in North America? Veterinary Clinics of North America: Food Animal Practice 28, 39–50.

Ruegg PI (2017) A 100-year review: mastitis detection, management, and prevention. Journal of Dairy Science 100, 10381–10397.

Sargeant JM and O’Connor AM (2014a) Introduction to systematic reviews in animal agriculture and veterinary medicine. Zoonoses and Public Health 61 (suppl. 1), 3–9.

Sargeant JM and O’Connor AM (2014b) Conducting systematic reviews of intervention questions II: relevance screening, data extraction, assessing risk of bias, presenting the results and interpreting the findings. Zoonoses and Public Health 61(suppl. 1), 39–51.

Sargeant JM, Elgie R, Valcour J, Saint-Onge J, Thompson A, Marcynuk P and McCann P (2009a) Methodological quality and completeness of reporting in clinical trials conducted in livestock species. Preventative Veterinary Medicine 91, 107–115.

Sargeant JM, Saint-Onge J, Valcour J, Thompson A, Elgie R, Snedeker K and Marcynuk P (2009b) Quality of reporting in randomized controlled trials of preharvest food safety interventions and associations with treatment effect. Foodborne Pathogens and Disease 6, 989–999.

Sargeant JM, O’Connor AM, Gardner IA, Dickson JS and Torrence ME and Consensus Meeting Participants (2010) The REFLECT statement: reporting guidelines for randomized controlled trials in livestock and food safety: explanation and elaboration. Zoonoses and Public Health 57, 105–136.

Sargeant JM, Kelton DF and O’Connor AM (2014a) Study designs and systematic reviews of interventions: building evidence across study designs. Zoonoses and Public Health 61(suppl. 1), 1–10.

Sargeant JM, Kelton DF and O’Connor AM (2014b) Randomized controlled trials and challenge trials: design and criterion for validity. Zoonoses and Public Health 61(suppl. 1), 18–27.

Sterne JAC, Gavaghan D and Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology 53, 1119–1129.

Totton SC, Cullen JN, Sargeant JM and O’Connor AM (2018) The reporting characteristics of bovine respiratory disease clinical intervention trials published prior to and following publication of the REFLECT statement. Preventative Veterinary Medicine 150, 117–125.

United States Department of Agriculture (2008) Antibiotic use on U.S. dairy operations, 2002 and 2007 Riverdale: United States department of agriculture, animal and plant health inspection service. Available from: https://www.aphis.usda.gov/animal_health/nahms/dairy/downloads/dairy07/Dairy07_is_AntibioticUse.pdf. (Accessed April 18, 2019).
van Knegsel AT, van der Drift SG, Cermakova J and Kemp B (2013) Effects of shortening the dry period of dairy cows on milk production, energy balance, health, and fertility: a systematic review. *The Veterinary Journal* **198**, 707–713.

Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software* **36**, 1–48.

Wellman NG and O’Connor AM (2007) Meta-analysis of treatment of cattle with bovine respiratory disease with tulathromycin. *Journal of Veterinary Pharmacology and Therapeutics* **30**, 234–241.

Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E and Peter T (2012) Developing core outcome sets for clinical trials: issues to consider. *Trials* **13**, 132; doi:10.1186/1745-6215-13-132.

Winder CB, Churchill KJ, Sargeant JM, LeBlanc SJ, O’Connor AM and Renaud DL (2019) Invited review: completeness of reporting of experiments: REFLECTing on a year of animal trials in the journal of dairy science. *Journal of Dairy Science* **102**, 4759–4771.

World Organisation for Animal Health (2007) OIE list of Antimicrobials of Veterinary Importance. Paris: World Organisation for Animal Health [cited 18th April 2019]. Available at https://www.oie.int/doc/ged/D9840.PDF.